Delivery Order SPE2DB22D2007-SPE2DB25FJ3LG
- Not listed
- The Defense Logistics Agency awarded a $13,844.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml SureClick auto-injectors. This non-set-aside, competitively awarded contract utilized firm fixed pricing and was completed on July 24, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of the company's established role as a critical pharmaceutical supplier to the...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors valued at $9,253.56 on July 30, 2025, with a completion date of July 31, 2025. This firm fixed price, non-competitive delivery order represents pharmaceutical procurement for military healthcare needs and is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, the company's corporate headquarters. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $13,729.56 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract utilizes firm fixed-price pricing with no set-aside designation, indicating competitive award. The delivery order is set to be completed by July 31, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within a...
- The Defense Logistics Agency awarded a $35,070.68 firm fixed price delivery order to AmerisourceBergen Drug Corp for ENBREL 50 MG/ML SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside contract was competitively awarded on July 22, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $101,132.02 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/mL SureClick auto-injectors. This firm fixed price, competitively awarded contract was executed on July 31, 2025, with an ultimate completion date of August 1, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting AmerisourceBergen's competitive capability in federal...
- The Defense Logistics Agency awarded a delivery order valued at $52,149.01 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. This competitive, non-set-aside contract carries a firm fixed price and was executed on August 1, 2025, with an ultimate completion date of August 4, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $35,026.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, which carries a completion date of July 28, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $10,537.97 to AmerisourceBergen Drug Corp for ENBREL 50 mg/ml SureClick auto-injectors on July 30, 2025, with a completion date of July 31, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $42,776.04 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL SureClick auto-injectors. The contract, awarded on July 24, 2025, with an ultimate completion date of July 25, 2025, represents a firm fixed-price procurement with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $35,063.69 delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/mL SureClick auto-injectors, with an ultimate completion date of July 24, 2025. This is a firm fixed-price delivery order issued under a competitive process with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving critical federal medical procurement needs, particularly for military and...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3LGDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $46,236.88 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 MG/ML SureClick auto-injectors. The contract, awarded on July 30, 2025, with an ultimate completion date of July 31, 2025, was competitively awarded with no set-aside designation and carries firm fixed pricing terms. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for federal military and veteran healthcare systems, supplying a comprehensive range of pharmaceutical products and medical supplies through the DLA's global pharmaceutical support vehicle. ENBREL, a biologic immunosuppressant used primarily for rheumatoid arthritis and other autoimmune conditions, supports Defense Health Agency patient care requirements across military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $46.2k | 7/30/25 |